Supernus Pharmaceuticals Inc (SUPN)
Financial leverage ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 1,368,070 | 1,277,670 | 1,702,510 | 1,689,150 | 1,504,100 |
| Total stockholders’ equity | US$ in thousands | 1,035,730 | 921,516 | 886,204 | 815,851 | 744,858 |
| Financial leverage ratio | 1.32 | 1.39 | 1.92 | 2.07 | 2.02 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,368,070K ÷ $1,035,730K
= 1.32
The financial leverage ratio of Supernus Pharmaceuticals Inc has shown fluctuations over the past five years. It increased from 2.02 in December 2020 to 2.07 in December 2021, indicating an increase in the company's reliance on debt to finance its operations. However, in the subsequent years, the ratio decreased to 1.92 in December 2022, 1.39 in December 2023, and further declined to 1.32 in December 2024.
A financial leverage ratio above 1 suggests that the company has more debt than equity in its capital structure, and a decreasing trend in the ratio indicates a reduction in the company's financial risk and dependency on borrowing. By consistently lowering its financial leverage ratio over the years, Supernus Pharmaceuticals Inc may be improving its financial stability and reducing its debt burden, which could positively impact its overall financial health and performance.
Peer comparison
Dec 31, 2024